TranS1 medical device company

Innovative, High-Tech, Transformational

TranS1 is a medical device company focused on providing elegant solutions to surgeons that minimize the damage caused by surgical approaches to the spine.   TranS1’s foundational solution, AxiaLIF+, requires only a 2 cm incision size, which reduces blood loss, inpatient stay, and interoperative time – all while achieving a 94% fusion rate.*

TranS1 Patents

TranS1’s research and development efforts align with two key aims: improving patient outcomes and making healthcare less expensive.

TranS1 in the News

TranS1 has been featured in a variety of publications. Learn more about our story and how we are striving to improve spine surgery technology.

Over 85 medical studies

See the full list of medical studies that support the safety and long-term outcomes of TranS1’s spinal fusion technology, such as AxiaLIF+.

Rocky Mountain Patent TranS1

Surgeon Driven

TranS1 intends to build our company into a vehicle to protect and commercialize surgeon innovations. TranS1’s CEO, Jeffrey Schell, is a patent attorney and the founder of Denver-based patent law firm Rocky Mountain Patent. This unique relationship enables the company to obtain and enforce intellectual property at a fraction of the costs that other medical device companies face.

TranS1 AxiaLIF biomechanical stability

Foundational

TranS1 develops products to solve spinal pathologies while minimizing trauma to the tissues surrounding the spine.  Our products build a strong foundation upon the L5-S1 joint to enable patients to enjoy better lives.  The “start with a strong foundation” philosophy is represented by the excellent biomechanical stability of our product line.

TranS1® has earned recognition for innovation, leadership, and the advancement of new technologies in Colorado from three leading business organizations.

*Citations Below

1. Bradley WD, Hisey MS, Verma-Kurvari S, Ohnmeiss DD. Minimally invasive trans-sacral approach to L5-S1 interbody fusion: Preliminary results from 1 center and review of the literature. Int J Spine Surg. 2012;6:110-4. PubMed PMID: 25694879; PubMed Central PMCID: PMC4300883.

2. Marchi L, Oliveira L, Coutinho E, Pimenta L. Results and complications after 2-level axial lumbar interbody fusion with a minimum 2-year follow-up. J Neurosurg Spine. 2012 Sep;17(3):187-92. PubMed PMID: 22803626.

3. Tobler WD, Gerszten PC, Bradley WD, Raley TJ, Nasca RJ, et al. Minimally invasive axial presacral L5-S1 interbody fusion: two-year clinical and radiographic outcomes. Spine (Phila Pa 1976). 2011 Sep 15;36(20):E1296-301. PubMed PMID: 21494201.

4. Aryan HE, Newman CB, Gold JJ, Acosta FL Jr, Coover C, Ames CP..2008. Percutaneous axial lumbar interbody fusion (AxiaLIF) of the L5-S1 segment: initial clinical and radiographic experience. Minim Invasive Neurosurg. 51(4):225-30. Pubmed PMID: 18683115

5. Mistry AM, Godil SS, Parker SL, McGirt MJ. Axial presacral lumbar interbody fusion: a systematic literature review. J Manag Care Med. 2014;17(3):47-56.